阿替利珠单抗联合贝伐珠单抗及非铂化疗治疗复发性卵巢癌:AGO-OVAR 2.29/ENGOT-ov34 III期试验最终结果
该双盲随机III期试验纳入574例铂类耐药复发性卵巢癌患者,随机接受阿替利珠单抗或安慰剂联合贝伐珠单抗及非铂化疗。安全性符合预期。
要点
- 阿替利珠单抗联合方案未显著改善铂类耐药复发性卵巢癌的OS和PFS。
- PD-L1状态不影响OS获益(HR相似)。
- ≥3级不良事件发生率阿替利珠单抗组72% vs 安慰剂组69%。
核心结论
- 在铂类不耐受的复发性卵巢癌患者中,阿替利珠单抗联合贝伐珠单抗及化疗未显著改善OS或PFS。
研究设计与样本
- 双盲随机III期AGO-OVAR 2.29/ENGOT-ov34试验(NCT03353831),纳入574例铂类治疗后≤6个月首次或第二次复发(或第三次复发不限无治疗间期)的卵巢癌患者。
- 患者1:1随机接受阿替利珠单抗840 mg或安慰剂每2周一次(最长2年),联合贝伐珠单抗及研究者选择的化疗(每周紫杉醇或聚乙二醇脂质体阿霉素),按既往治疗线数、计划化疗、既往贝伐珠单抗和PD-L1状态分层。
- 主要终点为意向治疗人群的OS和PFS。
主要发现
- 无论PD-L1状态如何,OS风险比相似。
- ≥3级不良事件发生率:阿替利珠单抗组72%,安慰剂组69%。
临床怎么用
- 对于铂类耐药的复发性卵巢癌,不推荐常规联合阿替利珠单抗与贝伐珠单抗及非铂化疗,因未显示显著生存获益。
局限性
- 原文未报告预设的PD-L1阳性亚组的具体疗效数据。
- OS分析时事件数未达到最终分析预设的事件数(原文仅报告418例死亡)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate atezolizumab combined with bevacizumab and non-platinum-based chemotherapy for recurrent ovarian cancer. METHODS: The double-blind randomized phase III AGO-OVAR 2.29/ENGOT-ov34 trial (ClinicalTrials.gov identifier: NCT03353831) enrolled patients with first or second relapse of ovarian cancer ≤6 months after completing platinum-based chemotherapy (or third relapse regardless of treatment-free interval). PD-L1 status was tested centrally (VENTANA SP142 assay) in recent (<3 months) biopsies before random assignment. All patients received bevacizumab and investigator-selected chemotherapy (once weekly paclitaxel or pegylated liposomal doxorubicin) until disease progression or toxicity, plus either atezolizumab 840 mg or placebo once every 2 weeks until progression (maximum 2 years), randomly assigned 1:1, and stratified by number of previous lines, planned chemotherapy, previous bevacizumab, and PD-L1 status. Primary end points were overall survival (OS) and progression-free survival (PFS) in the intention-to-treat population. RESULTS: Among 574 patients randomly assigned between September 2018 and July 2022, 72% were bevacizumab-pretreated, 36% had received three previous treatment lines, 26% had PD-L1-positive tumors, and 54% received paclitaxel with study therapy. After 418 patients had died, the hazard ratio for OS was 0.83 (95% CI, 0.68 to 1.01; P = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) and the hazard ratio for PFS was 0.87 (95% CI, 0.73 to 1.04; P = .12; median 6.4 v 6.7 months, respectively). OS hazard ratios were similar regardless of PD-L1 status. Grade ≥3 adverse events occurred in 72% of atezolizumab-treated and 69% of placebo patients. CONCLUSION: Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.
引用
- Harter P, Marmé F, Redondo A, et al. Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. J Clin Oncol. 2025. PMID: 41337696. doi:10.1200/JCO-25-01210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。